ORASURE TECHNOLOGIES, INC Cost of Revenue
ORASURE TECHNOLOGIES, INC (OSUR) reported Cost of Revenue of $17.32 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-07
- ORASURE TECHNOLOGIES, INC cost of goods and services sold for the quarter ending 2026-06-30 was $17.32M, a 4.21% decline year-over-year.
- ORASURE TECHNOLOGIES, INC cost of goods and services sold for the quarter ending 2026-03-31 was $16.12M, a 8.57% decline year-over-year.
- ORASURE TECHNOLOGIES, INC cost of goods and services sold for the quarter ending 2025-12-31 was $15.79M, a 33.85% decline year-over-year.
- ORASURE TECHNOLOGIES, INC cost of goods and services sold for the quarter ending 2025-09-30 was $15.31M, a 32.97% decline year-over-year.
- ORASURE TECHNOLOGIES, INC cost of goods and services sold for fiscal 2025 was $66.82M, a 37.22% decline from fiscal 2024.
- ORASURE TECHNOLOGIES, INC cost of goods and services sold for fiscal 2024 was $106.44M, a 54.48% decline from fiscal 2023.
- ORASURE TECHNOLOGIES, INC cost of goods and services sold for fiscal 2023 was $233.82M, a 2.18% decline from fiscal 2022.
- ORASURE TECHNOLOGIES, INC cost of goods and services sold for fiscal 2022 was $239.04M, a 105.94% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $17.32M 10-Q · filed 2026-08-07 | $33.44M 10-Q · filed 2026-08-07 | $49.24M derived: sum of 3 quarters · filed 2026-08-07 | $64.55M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | $16.12M 10-Q · filed 2026-05-08 | $31.92M derived: sum of 2 quarters · filed 2026-05-08 | $47.23M derived: sum of 3 quarters · filed 2026-05-08 | $65.31M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | $15.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $31.11M derived: sum of 2 quarters · filed 2026-03-09 | $49.19M derived: sum of 3 quarters · filed 2026-08-07 | $66.82M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $15.31M 10-Q · filed 2025-11-05 | $33.40M derived: sum of 2 quarters · filed 2026-08-07 | $51.03M 10-Q · filed 2025-11-05 | $74.91M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | $18.08M 10-Q · filed 2026-08-07 | $35.72M 10-Q · filed 2026-08-07 | $59.59M derived: sum of 3 quarters · filed 2026-08-07 | $82.44M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-03-31 | $17.63M 10-Q · filed 2026-05-08 | $41.51M derived: sum of 2 quarters · filed 2026-05-08 | $64.36M derived: sum of 3 quarters · filed 2026-05-08 | $94.00M derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | $23.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $46.72M derived: sum of 2 quarters · filed 2026-03-09 | $76.37M derived: sum of 3 quarters · filed 2026-03-09 | $106.44M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $22.84M 10-Q · filed 2025-11-05 | $52.49M derived: sum of 2 quarters · filed 2025-11-05 | $82.56M 10-Q · filed 2025-11-05 | $123.31M derived: sum of 4 quarters · filed 2026-03-09 | ||||
| 2024-06-30 | $29.65M 10-Q · filed 2025-08-06 | $59.71M 10-Q · filed 2025-08-06 | $100.47M derived: sum of 3 quarters · filed 2026-03-09 | $145.31M derived: sum of 4 quarters · filed 2026-03-09 | ||||
| 2024-03-31 | $30.07M 10-Q · filed 2025-05-07 | $70.82M derived: sum of 2 quarters · filed 2026-03-09 | $115.67M derived: sum of 3 quarters · filed 2026-03-09 | $174.74M derived: sum of 4 quarters · filed 2026-03-09 | ||||
| 2023-12-31 | $40.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $85.60M derived: sum of 2 quarters · filed 2026-03-09 | $144.67M derived: sum of 3 quarters · filed 2026-03-09 | $233.82M 10-K · filed 2026-03-09 | ||||
| 2023-09-30 | $44.85M 10-Q · filed 2024-11-06 | $103.92M derived: sum of 2 quarters · filed 2024-11-06 | $193.06M 10-Q · filed 2024-11-06 | $266.31M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2023-06-30 | $59.07M 10-Q · filed 2024-08-06 | $148.22M 10-Q · filed 2024-08-06 | $221.47M derived: sum of 3 quarters · filed 2025-03-07 | $291.42M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2023-03-31 | $89.15M 10-Q · filed 2024-05-09 | $162.40M derived: sum of 2 quarters · filed 2025-03-07 | $232.35M derived: sum of 3 quarters · filed 2025-03-07 | $284.78M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2022-12-31 | $73.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $143.20M derived: sum of 2 quarters · filed 2025-03-07 | $195.63M derived: sum of 3 quarters · filed 2025-03-07 | $239.04M 10-K · filed 2025-03-07 | $239.84M 10-K · filed 2023-03-03 | |||
| 2022-09-30 | $69.95M 10-Q · filed 2023-11-08 | $70.27M 10-Q · filed 2022-11-08 | $122.38M derived: sum of 2 quarters · filed 2023-11-08 | $165.79M 10-Q · filed 2023-11-08 | $166.35M 10-Q · filed 2022-11-08 | $202.23M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2022-06-30 | $52.43M 10-Q · filed 2023-08-04 | $52.65M 10-Q · filed 2022-08-09 | $95.84M 10-Q · filed 2023-08-04 | $96.08M 10-Q · filed 2022-08-09 | $132.28M derived: sum of 3 quarters · filed 2024-03-11 | $164.73M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2022-03-31 | $43.41M 10-Q · filed 2023-05-10 | $43.44M 10-Q · filed 2022-05-10 | $79.84M derived: sum of 2 quarters · filed 2024-03-11 | $112.29M derived: sum of 3 quarters · filed 2024-03-11 | $139.23M derived: sum of 4 quarters · filed 2024-03-11 | |||
| 2021-12-31 | $36.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $68.88M derived: sum of 2 quarters · filed 2024-03-11 | $95.82M derived: sum of 3 quarters · filed 2024-03-11 | $116.07M 10-K · filed 2024-03-11 | ||||
| 2021-09-30 | $32.45M 10-Q · filed 2022-11-08 | $59.38M derived: sum of 2 quarters · filed 2022-11-08 | $79.64M 10-Q · filed 2022-11-08 | $104.31M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2021-06-30 | $26.93M 10-Q · filed 2022-08-09 | $47.19M 10-Q · filed 2022-08-09 | $71.86M derived: sum of 3 quarters · filed 2023-03-03 | $89.58M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2021-03-31 | $20.26M 10-Q · filed 2022-05-10 | $44.93M derived: sum of 2 quarters · filed 2023-03-03 | $62.65M derived: sum of 3 quarters · filed 2023-03-03 | $74.64M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2020-12-31 | $24.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $42.39M derived: sum of 2 quarters · filed 2023-03-03 | $54.39M derived: sum of 3 quarters · filed 2023-03-03 | $69.85M 10-K · filed 2023-03-03 | ||||
| 2020-09-30 | $17.72M 10-Q · filed 2021-11-04 | $29.72M derived: sum of 2 quarters · filed 2021-11-04 | $45.18M 10-Q · filed 2021-11-04 | $65.01M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | $11.99M 10-Q · filed 2021-08-05 | $27.46M 10-Q · filed 2021-08-05 | $47.29M derived: sum of 3 quarters · filed 2022-03-01 | $61.63M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | $15.46M 10-Q · filed 2021-05-06 | $35.29M derived: sum of 2 quarters · filed 2022-03-01 | $49.64M derived: sum of 3 quarters · filed 2022-03-01 | $63.45M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | $19.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $34.17M derived: sum of 2 quarters · filed 2022-03-01 | $47.98M derived: sum of 3 quarters · filed 2022-03-01 | $60.02M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $14.34M 10-Q · filed 2020-11-05 | $28.15M derived: sum of 2 quarters · filed 2020-11-05 | $40.19M 10-Q · filed 2020-11-05 | $55.73M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $13.81M 10-Q · filed 2020-08-06 | $25.85M 10-Q · filed 2020-08-06 | $41.39M derived: sum of 3 quarters · filed 2021-03-01 | $58.73M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $12.04M 10-Q · filed 2020-05-11 | $27.58M derived: sum of 2 quarters · filed 2021-03-01 | $44.92M derived: sum of 3 quarters · filed 2021-03-01 | $62.65M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $15.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $32.88M derived: sum of 2 quarters · filed 2021-03-01 | $50.61M derived: sum of 3 quarters · filed 2021-03-01 | $68.13M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $17.34M 10-Q · filed 2019-11-08 | $35.07M derived: sum of 2 quarters · filed 2019-11-08 | $52.59M 10-Q · filed 2019-11-08 | $76.09M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-06-30 | $17.73M 10-Q · filed 2019-08-07 | $35.25M 10-Q · filed 2019-08-07 | $58.75M derived: sum of 3 quarters · filed 2020-03-02 | $76.42M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-03-31 | $17.52M 10-Q · filed 2019-05-09 | $41.02M derived: sum of 2 quarters · filed 2020-03-02 | $58.69M derived: sum of 3 quarters · filed 2020-03-02 | $73.39M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2017-12-31 | $23.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $41.17M derived: sum of 2 quarters · filed 2020-03-02 | $55.87M derived: sum of 3 quarters · filed 2020-03-02 | $68.11M 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | $17.67M 10-Q · filed 2018-11-08 | $32.37M derived: sum of 2 quarters · filed 2018-11-08 | $44.60M 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | $14.70M 10-Q · filed 2018-08-09 | $26.93M 10-Q · filed 2018-08-09 | ||||||
| 2016-12-31 | $40.17M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |